These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 16861119)

  • 1. Update on radiation therapy in prostate cancer.
    Lee AK; Frank SJ
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):857-78. PubMed ID: 16861119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technological advances in radiotherapy for the treatment of localised prostate cancer.
    Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A
    Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy.
    Al-Salihi O; Mitra A; Payne H
    Prostate Cancer Prostatic Dis; 2006; 9(4):370-3. PubMed ID: 16832383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent developments in radiation oncology-integrating radiation physics and molecular radiobiology advances into clinical radiotherapy practice and beyond].
    Teh BS; Paulino A; Butler EB
    Ai Zheng; 2008 Aug; 27(8):885-93. PubMed ID: 18710628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
    Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
    Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose external beam radiation for localized prostate cancer: current status and future challenges.
    Nguyen PL; Zietman AL
    Cancer J; 2007; 13(5):295-301. PubMed ID: 17921728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated radiation therapy dose prescription, recording, and delivery: patterns of variability among institutions and treatment planning systems.
    Das IJ; Cheng CW; Chopra KL; Mitra RK; Srivastava SP; Glatstein E
    J Natl Cancer Inst; 2008 Mar; 100(5):300-7. PubMed ID: 18314476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-escalated 3D conformal radiotherapy in prostate cancer.
    Malone S
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):663-8. PubMed ID: 15270669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy.
    Koontz BF; Das S; Temple K; Bynum S; Catalano S; Koontz JI; Montana GS; Oleson JR
    Med Dosim; 2009; 34(3):256-60. PubMed ID: 19647638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors.
    Palm A; Johansson KA
    Acta Oncol; 2007; 46(4):462-73. PubMed ID: 17497313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second cancers in children treated with modern radiotherapy techniques.
    Schneider U; Lomax A; Timmermann B
    Radiother Oncol; 2008 Nov; 89(2):135-40. PubMed ID: 18707783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer.
    Efstathiou JA; Trofimov AV; Zietman AL
    Cancer J; 2009; 15(4):312-8. PubMed ID: 19672148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer.
    Schneider U; Lomax A; Besserer J; Pemler P; Lombriser N; Kaser-Hotz B
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):892-7. PubMed ID: 17459608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of spatial dose gradients and probability density function to evaluate the effect of internal organ motion for prostate IMRT treatment planning.
    Jiang R; Barnett RB; Chow JC; Chen JZ
    Phys Med Biol; 2007 Mar; 52(5):1469-84. PubMed ID: 17301465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer.
    Luo C; Yang CC; Narayan S; Stern RL; Perks J; Goldberg Z; Ryu J; Purdy JA; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1253-62. PubMed ID: 17145540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
    Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
    Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment plan comparison between helical tomotherapy and MLC-based IMRT using radiobiological measures.
    Mavroidis P; Ferreira BC; Shi C; Lind BK; Papanikolaou N
    Phys Med Biol; 2007 Jul; 52(13):3817-36. PubMed ID: 17664579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
    Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
    Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.